What prostate cancer actually is
Start here. A short, jargon-free picture of the disease before we get into tests and treatment.
The prostate is a small gland — about the size of a ping-pong ball — that sits just below the bladder and wraps around the urethra (the tube urine flows through). It makes fluid that helps carry sperm. Prostate cancer begins when cells in that gland start growing out of control.
Cancer cells don't play by the usual rules: they multiply when they shouldn't, avoid the natural death that normal cells go through, crowd out healthy cells, and can eventually spread. Prostate cancer is one of the most common cancers in men — but it also tends to grow slowly, and it often causes no symptoms for a long time.
When it's found early, prostate cancer has one of the highest survival rates of any cancer. Many people live for years — often the rest of their lives — without it causing serious problems, and not everyone even needs treatment right away.
Early-stage vs. advanced — the words you'll hear
Localized (early-stage)
Cancer is still contained inside the prostate. It usually grows slowly and stays put. This is the most treatable situation.
Regional (locally advanced)
Cancer has grown just outside the prostate to nearby tissue or lymph nodes — but no farther. Roughly 1 in 8 diagnoses.
Distant metastatic
Cancer has spread beyond the pelvis to places like the bones, distant lymph nodes, liver, or lungs. Treatable, though usually long-term.
Symptoms — often none at all
Especially early on, prostate cancer frequently causes no symptoms. When symptoms do appear they can include urinating often (especially at night), a weak or stop-start stream, trouble starting or holding urine, a feeling the bladder isn't empty, blood in the urine or semen, erectile difficulties, or pain in the groin, hips, back, or bones.
An enlarged prostate — a non-cancerous condition called BPH — is far more common than cancer and causes many of the same urinary symptoms. You can't tell them apart by symptoms alone, so tell your doctor about anything you notice rather than trying to self-diagnose.
What raises the risk?
A risk factor is anything that increases your chance of getting a disease — it doesn't mean you'll definitely get it. For prostate cancer the main ones are:
#1 Age
Age is the biggest factor. Most prostate cancers are diagnosed in people over 65, and the chance rises as you get older.
Family Family & inherited genes
Having a father or brother with prostate cancer raises your risk. A family history of breast, ovarian, colon, or pancreatic cancer can matter too.
Sometimes an inherited gene change is involved — for example a change in the BRCA2 gene. If cancer seems to "run in the family," genetic testing and counseling may be suggested (more on this under Diagnosis).
Race Race and access to care
In the U.S., Black men are more likely to develop prostate cancer, often at a younger age and in a more aggressive form, and are about twice as likely to die from it. Unequal access to care is a major reason. Black men may want to talk with their doctor about starting screening earlier. Hispanic and Asian men are less likely to be diagnosed than white or Black men.
Lifestyle Diet, weight, and smoking
No single diet causes or prevents prostate cancer, but diets high in fat (a lot of meat and dairy) are linked to higher risk, while more fruits and vegetables, exercise, and a healthy weight are linked to lower risk and less aggressive disease. Smoking and obesity raise the risk of developing it and of dying from it.
The tests, and what each one is for
Not everyone gets every test. Testing usually moves from simple screening → confirming cancer with a biopsy → figuring out how far it has spread.
The two screening tests
PSA blood test
Measures prostate-specific antigen, a protein made by the prostate. A high level can be a sign of cancer — but an enlarged prostate, infection, or even recent exercise can raise it too, so it's rarely used alone.
Digital rectal exam
The doctor feels the prostate through the rectum with a gloved finger to check its size and texture. A hard or irregular area can be a sign of a tumor. Quick, and often paired with the PSA test.
If these and your personal factors (age, family history, race) raise concern, you may have extra biomarker blood or urine tests (with names like PHI, 4Kscore, SelectMDx, MPS, IsoPSA, or ExoDx) to help decide whether a biopsy is truly needed.
A list of all your medicines and supplements. Some — like saw palmetto or St. John's wort — can change your PSA level or interfere with treatment, so your team needs to know about them.
Imaging — pictures of the inside
Imaging shows the size and location of the cancer and whether it has spread. Early, low-risk cancer often doesn't need it; higher-risk cancer usually does.
MRI MRI & mpMRI
Uses magnets and radio waves (no x-rays) for a detailed view of the prostate and nearby lymph nodes or pelvic bones. A multiparametric MRI (mpMRI) combines several scan types for an even clearer picture and can help target a biopsy. (No metal in the scan room.)
CT CT scan
Combines many x-rays into a detailed cross-section. Good for checking lymph nodes and the area around the prostate for spread.
PET PET & PSMA-PET
A PET scan uses a small amount of radioactive tracer that lights up cancer cells. PSMA-PET uses a tracer that locks onto PSMA, a protein prostate cancer cells make a lot of — especially useful for spotting small areas of spread and for watching for the cancer coming back.
Bone Bone scan & ultrasound
A bone scan uses a tracer to reveal whether cancer has reached the bones. Ultrasound (TRUS) uses sound waves through a rectal probe, mainly to guide a biopsy; MRI images can be blended with it (MRI-TRUS fusion) for more precise sampling.
Biopsy — the only way to confirm cancer
Imaging and PSA can raise suspicion, but the only way to know for sure is a biopsy: a hollow needle removes tiny cores of tissue (usually 12 or more, from different areas) that a pathologist examines under a microscope. It won't cause the cancer to spread.
Transrectal
- Needle passes through the rectal wall into the prostate, guided by ultrasound
- Usually done awake in the office with numbing medicine
- Antibiotics are given because infection is a real risk this way
Transperineal
- Needle enters through the skin between the scrotum and anus
- May use general or local anesthesia; lower infection risk
- Takes roughly 20–40 minutes
Genetic testing — two different kinds
Inherited Germline (inherited) testing
Looks for gene changes you were born with — present in every cell and passable to your children. Done from blood, saliva, or urine. For prostate cancer it checks genes like BRCA1, BRCA2, ATM, CHEK2, and others.
It's recommended if you have a relevant family history, high/very-high-risk, regional, or metastatic cancer, Ashkenazi Jewish ancestry, or another cancer. A genetic counselor can help you decide and understand results.
Tumor Tumor (somatic) testing
Looks at the cancer itself — from biopsy tissue or a blood "liquid biopsy" — for changes that appeared only in the tumor. This can unlock targeted therapies (such as PARP inhibitors) for cancers with certain DNA-repair gene changes. About 1 in 4 people with advanced, hormone-resistant prostate cancer have this kind of mutation.
Making sense of the numbers
Your PSA, Gleason score / Grade Group, and stage combine into a "risk group" that guides treatment. Here's how to read each piece.
PSA — and why "normal" depends on age
PSA is measured in nanograms per milliliter (ng/mL). It naturally tends to rise with age, so what counts as suspicious changes over time. A level of 10 or higher is a warning sign at any age. Doctors also look at PSA density (PSA compared to prostate size) — above about 0.15 suggests a higher chance of cancer.
| Age | Typical range |
|---|---|
| 40–49 | 0.0 – 2.5 ng/mL |
| 50–59 | 2.5 – 3.5 ng/mL |
| 60–69 | 3.5 – 4.5 ng/mL |
| 70–79 | 4.5 – 6.5 ng/mL |
A larger prostate makes more PSA; on average Black men have slightly higher readings; and PSA rises for a few days after a biopsy, ejaculation, or vigorous exercise — so timing matters.
Gleason score & Grade Group — how aggressive is it?
Under the microscope, the pathologist rates how abnormal the cancer cells look, from pattern 3 to 5. They add the two most common patterns together to get a Gleason score (most cancers land between 6 and 10). Because "6 out of 10" sounds middling when it's actually the lowest, these are now simplified into Grade Groups 1–5. Note that 3+4 and 4+3 both equal 7, but 4+3 is more serious because the larger, more aggressive pattern comes first.
| Gleason | Grade Group | Grade | Meaning |
|---|---|---|---|
| 6 (3+3) | Group 1 | Low | Least aggressive; may grow so slowly it never needs treatment. |
| 7 (3+4) | Group 2 | Low–Int. | Favorable; dominant pattern is still the calmer one. |
| 7 (4+3) | Group 3 | Intermediate | More serious than Group 2 — aggressive pattern dominates. |
| 8 | Group 4 | High | Aggressive; likely to grow and spread; treatment usually needed. |
| 9–10 | Group 5 | Very high | Most aggressive; grows and spreads quickly. |
Stage — the TNM shorthand
Staging describes how much cancer there is and how far it's traveled, using three letters:
Tumor
Size and extent of the main tumor (T0–T4). Higher numbers mean it has grown further, eventually into nearby structures.
Node
Whether it has reached nearby lymph nodes. N0 = no; N1 = yes.
Metastasis
Whether it has spread to distant parts of the body. M0 = no; M1 = yes.
Example: T2, N0, M0 means a tumor big enough to feel, but no spread to lymph nodes or distant sites.
Putting it together: risk groups
Your PSA, Grade Group, stage, and how much cancer was in the biopsy cores combine into a risk group. Using them together is more reliable than any single test. Lower-risk groups often get little or no immediate treatment; higher-risk groups get more.
| Risk group | Rough picture |
|---|---|
| Very low | Tiny amount, Grade Group 1, low PSA and PSA density — barely detectable. |
| Low | Grade Group 1, PSA under 10, confined to the prostate. |
| Favorable intermediate | One intermediate factor; Grade Group 1–2; less than half of cores involved. |
| Unfavorable intermediate | More intermediate factors, Grade Group 3, or more than half of cores involved. |
| High / very high | Higher PSA, Grade Group 4–5, or growth outside the prostate. More aggressive treatment. |
Two more tools help personalize the picture: life expectancy (an estimate that shapes how aggressive treatment should be), nomograms (calculators that compare you to thousands of past patients), and molecular tumor tests (like Decipher, Oncotype DX, or Prolaris) — which can flag cancers so low-risk they can safely be watched rather than treated.
The full toolkit, explained
Treatments fall into a few families. Many plans combine them. Don't worry about memorizing everything — this is a reference you can return to.
Because surgery and radiation have similar cure rates for early cancer, it's worth seeing both a urologist and a radiation oncologist before deciding. And a second opinion is a completely normal, expected part of cancer care.
Watching, not treating (yet)
Sometimes the best first step is careful monitoring — but there are two different versions, and they're easy to confuse:
Active surveillance
- Goal: cure it later if needed, while avoiding side effects now
- Regular PSA tests, exams, MRI, and repeat biopsies
- Switch to treatment if the cancer grows (often shown by a rising Grade Group)
Observation (watchful waiting)
- Goal: keep quality of life, treat symptoms if they appear
- Lighter monitoring — a PSA and check-up once or twice a year
- No routine biopsies; treatment aims at comfort, not cure
Local treatments (aimed at the prostate)
Surgery Radical prostatectomy
Removes the whole prostate and seminal vesicles (and sometimes nearby lymph nodes). Most surgery today is minimally invasive / robot-assisted — smaller cuts, less blood loss, faster recovery — with side-effect rates similar to open surgery. The goal is a "negative margin" (no cancer cells at the edge of what's removed).
Main side effects: urinary leakage (usually temporary; pelvic-floor exercises help) and erectile dysfunction (may take months to two years to improve, and may not fully return). Removing the prostate also means dry orgasms and infertility — ask about sperm banking beforehand if that matters to you.
Radiation External beam radiation (EBRT)
A machine aims precise radiation at the cancer from outside the body, over a series of sessions. Modern forms (IMRT, 3D-CRT, SBRT, proton, image-guided) shape the beam to the tumor to spare healthy tissue. Can be used instead of surgery, or after surgery if PSA rises.
Common side effects: urinary and bowel changes (urgency, frequency, diarrhea), fatigue, and erectile dysfunction — many ease over weeks.
Radiation Brachytherapy (internal seeds)
Places radioactive sources inside the prostate. Low-dose-rate (LDR) uses permanent rice-sized "seeds"; high-dose-rate (HDR) uses temporary needles that deliver a strong dose and are then removed. Often used alone for lower-risk cancer, or combined with EBRT and hormone therapy for higher-risk cancer.
Hormone therapy (ADT) — cutting off the fuel
Prostate cancer feeds on male hormones (androgens), mainly testosterone. Androgen deprivation therapy (ADT) either stops the body making testosterone or blocks cancer cells from using it — starving the cancer to shrink it or slow it down. The target is a very low "castrate" level.
ADT is rarely used alone for early cancer (it's usually paired with radiation), but it's the backbone of treatment for advanced disease. "Castration" simply means a drastic drop in testosterone — achieved with reversible drugs or, less commonly now, by surgically removing the testicles (orchiectomy).
| Family | How it works | Examples |
|---|---|---|
| LHRH / GnRH agonists | Switch off the testicles' testosterone production. Cause a brief early "flare" (a testosterone spike) that can be blocked with an anti-androgen. | leuprolide (Lupron), goserelin (Zoladex), triptorelin (Trelstar) |
| LHRH / GnRH antagonists | Block the brain's signal directly — testosterone drops fast with no flare. One (relugolix) is a daily pill. | degarelix (Firmagon), relugolix (Orgovyx) |
| Anti-androgens (AR blockers) | Block the receptor so testosterone can't dock. Newer "next-generation" ones extend life and delay spread. | enzalutamide (Xtandi), apalutamide (Erleada), darolutamide (Nubeqa), bicalutamide |
| Androgen-synthesis inhibitors | Shut off the backup testosterone the adrenal glands and tumor still make. Given with a steroid. | abiraterone (Zytiga), ketoconazole |
Over time some cancers learn to grow even when testosterone is very low. This is called hormone-resistant or castration-resistant prostate cancer. It's still treatable — people usually stay on ADT to keep testosterone down, and other therapies are added on top.
Systemic treatments beyond hormones (mainly for advanced cancer)
Chemo Chemotherapy
Attacks fast-dividing cells throughout the body. Docetaxel is the main one (given into a vein every 3 weeks with a steroid) — it can't cure prostate cancer but helps people live longer and eases symptoms. Others include cabazitaxel, carboplatin/cisplatin, and mitoxantrone (for pain).
Immune Immunotherapy
Sipuleucel-T (Provenge) is a "cancer vaccine" that trains your own immune cells against the cancer, for hormone-resistant disease with few symptoms. Pembrolizumab (Keytruda) is a checkpoint inhibitor used for the small group whose tumors have specific genetic features.
Targeted Targeted therapy (PARP inhibitors)
For cancers with BRCA or other DNA-repair gene changes, PARP inhibitors — olaparib (Lynparza), rucaparib (Rubraca), niraparib+abiraterone (Akeega), talazoparib+enzalutamide (Talzenna) — block a repair pathway the cancer relies on. This is why tumor genetic testing matters.
Radio Radiopharmaceuticals
Medicines carrying radiation directly to cancer cells. Lutetium-177 (Pluvicto) homes in on the PSMA protein anywhere in the body (needs a PSMA-PET scan first). Radium-223 (Xofigo) collects in bones to treat bone metastases and ease bone pain.
Bone Bone-targeted therapy
Denosumab (Prolia/Xgeva) and zoledronic acid (Zometa) strengthen bone, prevent fractures, and help with bone loss — important both for bone metastases and to offset ADT's effect on the skeleton.
For advanced cancer, ADT is rarely given alone anymore. Adding one more drug is doublet therapy; adding two is triplet therapy (for example ADT + docetaxel chemo + a next-generation hormone medicine). Combining treatments up front often helps people live longer with fewer symptoms.
Clinical trials
A clinical trial tests a promising new treatment. You may receive tomorrow's therapy today, and you can ask about trials at any point — you don't have to be "out of options." Placebos are almost never used alone in cancer trials (usually a new drug or placebo is added on top of standard treatment), and there's no fee to enroll. Black men are underrepresented in trials, so asking is especially worthwhile.
Typical options by stage & risk
Pick where things stand to see the kinds of options usually considered. Life expectancy and your own preferences shape the choice — this is a general map, not a personalized recommendation.
Real decisions weigh your age and health, how the cancer looks under the microscope, your test results, and what matters to you. Use this to prepare questions — then let your care team tailor the plan.
Managing side effects and looking after you
Side effects are real, but most can be softened. Support for your body and your mind is part of good cancer care — at every stage, not just the end.
Living with hormone therapy
Because ADT lowers testosterone, it can cause hot flashes, fatigue, mood changes, weight gain, reduced sex drive and erectile dysfunction, breast tenderness, and loss of muscle. Over time it can thin the bones and raise the risk of diabetes and heart disease.
Regular physical activity measurably reduces fatigue, weight gain, and bone and muscle loss from ADT — and improves mood. Ask your team to help you find a program that fits you.
Protect your bones
Expect a bone-density (DEXA) scan around the start of ADT and after a year. Bone-strengthening medicines plus calcium and vitamin D can help.
Mind your heart
Ask about monitoring blood pressure, cholesterol, and blood sugar, and keep your primary care doctor in the loop about being on ADT.
Sexual health
Options for erectile dysfunction include pills, injections, vacuum devices, and implants. Counseling — solo or with a partner — genuinely helps.
Your emotional health matters too
Anxiety and depression are common with prostate cancer — and erectile dysfunction is a leading cause of depression here. These feelings deserve care just like physical symptoms. Support groups, talk therapy, and medication all help, and cancer centers have social workers and patient navigators to connect you.
Ongoing sadness, loss of interest, anxiety, or sleep trouble shouldn't be toughed out alone. Let your care team know — help is available, and asking for it is part of taking care of yourself.
Supportive care, money, and planning ahead
Supportive (palliative) care treats symptoms and side effects and supports you emotionally and practically — and everyone with advanced cancer should be offered it, starting early, because it improves quality of life. If cost becomes a strain (treatment, travel, missed work, insurance gaps), a hospital social worker or financial counselor can help find support. And advance care planning — thinking through what you'd want — is for everyone starting treatment, not only those who are very ill.
You're the expert on you
Good care is a partnership. Your team brings the medical expertise; you bring your values, priorities, and what quality of life means to you.
A strong team should walk you through the likely benefits and harms of each option, the odds of cure or recurrence, and how each choice could affect your daily life — including sexual, urinary, and bowel function. In return, share openly how you feel about side effects, risks, and what you most want to protect. If no one raises shared decision-making, it's fine to ask for it.
- What is my risk group and stage, and what does that mean for me?
- Is active surveillance a reasonable option — why or why not?
- What are the realistic side effects of each treatment you're recommending?
- Should I see both a surgeon and a radiation oncologist?
- Do my results call for genetic testing or a molecular tumor test?
- Is there a clinical trial I might be eligible for?
- Who do I call with questions, and how do we track whether treatment is working?
It's natural to want to start immediately, but for most prostate cancer there is time to gather your results, get a second (or third) opinion, and talk it through with people you trust before you decide.